Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0E5DP
|
||||
Former ID |
DNCL002705
|
||||
Drug Name |
Cixutumumab
|
||||
Synonyms |
LY3012217
|
||||
Drug Type |
Monoclonal antibody
|
||||
Indication | Liver cancer; Non-small cell lung cancer [ICD9: 140-229, 155, 203.0; ICD10:C22, C33-C34] | Phase 2 | [523234] | ||
Company |
Lilly
|
||||
CAS Number |
CAS 947687-12-9
|
||||
Target and Pathway | |||||
Target(s) | Insulin-like growth factor I receptor | Target Info | Modulator | [533208] | |
KEGG Pathway | Ras signaling pathway | ||||
Rap1 signaling pathway | |||||
HIF-1 signaling pathway | |||||
FoxO signaling pathway | |||||
Oocyte meiosis | |||||
Endocytosis | |||||
PI3K-Akt signaling pathway | |||||
AMPK signaling pathway | |||||
Focal adhesion | |||||
Adherens junction | |||||
Signaling pathways regulating pluripotency of stem cells | |||||
Long-term depression | |||||
Ovarian steroidogenesis | |||||
Progesterone-mediated oocyte maturation | |||||
Pathways in cancer | |||||
Transcriptional misregulation in cancer | |||||
Proteoglycans in cancer | |||||
Glioma | |||||
Prostate cancer | |||||
Melanoma | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.